Elan Corporation PLC Announces First European Commission Approval of Injectable Treatment Using NanoCrystal(R) Technology

Published: Mar 10, 2011

DUBLIN--(BUSINESS WIRE)--Elan Drug Technologies (EDT), the drug delivery unit of Elan Corporation, plc (NYSE: ELN), today announced that the first injectable product using EDT’s NanoCrystal® technology has been approved by the European Commission. XEPLION®, Janssen-Cilag International NV’s long-acting injectable treatment for patients with schizophrenia which uses EDT’s NanoCrystal® technology, was approved by the European Commission earlier today.

Back to news